Factors Influencing the Recurrence of a Giant Cell Tumor of the Bone.
10.4055/jkoa.2005.40.1.44
- Author:
Han Sik KIM
1
;
Sung Hwan KIM
;
Kyoo Ho SHIN
;
Soo Bong HAHN
Author Information
1. Department of Orthopaedic Surgery, Jeil Hospital, Seoul, Korea. qshin@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Giant cell tumor of the bone;
The incidence of a recurrence
- MeSH:
Follow-Up Studies;
Fractures, Spontaneous;
Giant Cell Tumors*;
Giant Cells*;
Humans;
Incidence;
Neoplasm Metastasis;
Polymethyl Methacrylate;
Recurrence*;
Retrospective Studies;
Transplants
- From:The Journal of the Korean Orthopaedic Association
2005;40(1):44-49
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to evaluate the recurrence rates of a giant cell tumor of the bone an determine what, if any, patient factors, tumor characteristics and surgical treatments correlate with the incidence of a local recurrence. MATERIALS AND METHODS: The records of fifty two cases who were diagnosed with a giant cell tumor of the bone between March 1992 and March 2001 and were could be followed up for at least 2 years were analysed retrospectively. This study reviewed the clinical characters, and the treatment method, recurrence, complication, the result of the follow-up. A Fisher' exact test was carried out to analyse the statistics. RESULTS: Sixteen patients (31%)had a local recurrence. The average time to recurrence was 17 months. All but case one recurred within 2 years after receiving surgical treatment. There was no significant differences in the recurrence rates based on the following variables: gender, tumor location, Campanacci grade, the presence of a pathologic fracture, primary versus recurrent tumor at presentation, resection margin, the use of a bone graft, internal fixation or polymethylmethacrylate. CONCLUSION: The clinical characters and methods of treatment were not correlated with a local recurrence. Most recurrences of a giant cell tumor can be expected within the first two to three years. Therefore the patient needs to be followed up in that period and longer for the a late recurrence and pulmonary metastasis.
